Literature DB >> 31435529

The IncRNA BORG: A novel inducer of TNBC metastasis, chemoresistance, and disease recurrence.

Alex J Gooding1, Kimberly A Parker2, Saba Valadkhan3, William P Schiemann4.   

Abstract

Although greater than 90% of breast cancer-related mortality can be attributed to metastases, the molecular mechanisms underpinning the dissemination of primary breast tumor cells and their ability to establish malignant lesions in distant tissues remain incompletely understood. Genomic and transcriptomic analyses identified a class of transcripts called long noncoding RNA (lncRNA), which interact both directly and indirectly with key components of gene regulatory networks to alter cell proliferation, invasion, and metastasis. We identified a pro-metastatic lncRNA BORG whose aberrant expression promotes metastatic relapse by reactivating proliferative programs in dormant disseminated tumor cells (DTCs). BORG expression is broadly and strongly induced by environmental and chemotherapeutic stresses, a transcriptional response that facilitates the survival of DTCs. Transcriptomic reprogramming in response to BORG resulted in robust signaling via survival and viability pathways, as well as decreased activation of cell death pathways. As such, BORG expression acts as a (i) marker capable of predicting which breast cancer patients are predisposed to develop secondary metastatic lesions, and (ii) unique therapeutic target to maximize chemosensitivity of DTCs. Here we review the molecular and cellular factors that contribute to the pathophysiological activities of BORG during its regulation of breast cancer metastasis, chemoresistance, and disease recurrence.

Entities:  

Keywords:  BORG; TNBC; chemoresistance; disease recurrence; dormancy; lncRNA; metastasis

Year:  2019        PMID: 31435529      PMCID: PMC6703157          DOI: 10.20517/2394-4722.2019.11

Source DB:  PubMed          Journal:  J Cancer Metastasis Treat        ISSN: 2394-4722


  107 in total

Review 1.  NF-kappaB as a primary regulator of the stress response.

Authors:  F Mercurio; A M Manning
Journal:  Oncogene       Date:  1999-11-01       Impact factor: 9.867

2.  Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery.

Authors:  Rona M MacKie; Robin Reid; Brian Junor
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

3.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

Review 4.  The role of NF-kappaB in the regulation of cell stress responses.

Authors:  Tieli Wang; Xia Zhang; Jian Jian Li
Journal:  Int Immunopharmacol       Date:  2002-10       Impact factor: 4.932

5.  The tumor microenvironment as a determinant of drug response and resistance.

Authors:  William S. Dalton
Journal:  Drug Resist Updat       Date:  1999-10       Impact factor: 18.500

6.  Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.

Authors:  George N Naumov; Ian C MacDonald; Pascal M Weinmeister; Nancy Kerkvliet; Kishore V Nadkarni; Sylvia M Wilson; Vincent L Morris; Alan C Groom; Ann F Chambers
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

7.  Structure of the RPA trimerization core and its role in the multistep DNA-binding mechanism of RPA.

Authors:  Elena Bochkareva; Sergey Korolev; Susan P Lees-Miller; Alexey Bochkarev
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

Review 8.  Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.

Authors:  Lori A Hazlehurst; Terry H Landowski; William S Dalton
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

9.  Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases.

Authors:  George N Naumov; Jason L Townson; Ian C MacDonald; Sylvia M Wilson; Vivien H C Bramwell; Alan C Groom; Ann F Chambers
Journal:  Breast Cancer Res Treat       Date:  2003-12       Impact factor: 4.872

10.  Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2.

Authors:  Johnson M S Wong; Daniela Ionescu; C James Ingles
Journal:  Oncogene       Date:  2003-01-09       Impact factor: 9.867

View more
  5 in total

1.  lncRNA BORG:TRIM28 Complexes Drive Metastatic Progression by Inducing α6 Integrin/CD49f Expression in Breast Cancer Stem Cells.

Authors:  Kimberly A Parker; Alex J Gooding; Saba Valadkhan; William P Schiemann
Journal:  Mol Cancer Res       Date:  2021-09-08       Impact factor: 5.852

2.  Long Non-coding RNA BTG3-7:1 and JUND Co-regulate C21ORF91 to Promote Triple-Negative Breast Cancer Progress.

Authors:  Zheng Dan; He Xiujing; Luo Ting; Zhong Xiaorong; Zheng Hong; Yang Jiqiao; Li Yanchu; Jing Jing
Journal:  Front Mol Biosci       Date:  2021-01-29

Review 3.  TGFβ signaling networks in ovarian cancer progression and plasticity.

Authors:  Asha Kumari; Zainab Shonibare; Mehri Monavarian; Rebecca C Arend; Nam Y Lee; Gareth J Inman; Karthikeyan Mythreye
Journal:  Clin Exp Metastasis       Date:  2021-02-15       Impact factor: 5.150

4.  DCAF13 promotes breast cancer cell proliferation by ubiquitin inhibiting PERP expression.

Authors:  Bao-Qian Shan; Xiao-Min Wang; Li Zheng; Yao Han; Jie Gao; Meng-Dan Lv; Yi Zhang; Yi-Xuan Liu; Han Zhang; Hao-Sa Chen; Lei Ao; Yin-Li Zhang; Xiang Lu; Zhong-Jie Wu; Ying Xu; Xuan Che; Michal Heger; Shu-Qun Cheng; Wei-Wei Pan; Xin Zhang
Journal:  Cancer Sci       Date:  2022-03-18       Impact factor: 6.518

5.  Introduction to this special issue "Breast Cancer Metastasis".

Authors:  William P Schiemann
Journal:  J Cancer Metastasis Treat       Date:  2020-02-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.